0
Title
User
LIVE NOW
LIVE NOW
Title
User
Schedule An Interview
Schedule A Remote Interview with OncologyTube
Home
Trending
Sign In
Audios and Videos
Videos
Audios
Channels
Browse Channels
Categories
Acute Lymphoblastic Leukemia
5645
Acute Myelogenous Leukemia
200
Bladder Cancer
67
Bone Metastases
2
Brain Cancer
59
Breast Cancer
223
Business Management
3
Cervical Cancer
6
Chronic Lymphocytic Leukemia
192
Chronic Myelogenous Leukemia
43
Colorectal Cancer
106
COVID-19
27
Gastrointestinal Cancer
88
General
319
Head and Neck Cancers
72
Hematologic Malignancies
180
Hodgkin Lymphoma
28
Immunotherapy
153
Kidney Cancer
374
Liver Cancer
25
Lymphoma
179
Melanoma and Skin Cancer
57
Multiple Myeloma
459
Myeloproliferative Disease
19
News
147
Non-Hodgkin Lymphoma
76
Non-Small Cell Lung Cancer
408
Other
241
Ovarian Cancer
43
Pancreatic Cancer
72
Patient Resources
28
Pediatric Cancer
3
Prostate Cancer
218
Sickle Cell
21
Small Cell Lung Cancer
71
Soft Tissue Sarcoma
10
Supportive Care
47
Testicular Cancer
2
Urology
14
Uterine Cancer
7
About
Contact
00:00:36
I-O Treatment vs. TKI Treatment | TKI is Still Standard of Care for Good-Risk Patients
Eric Jonasch, MD, UT MD Anderson Cancer Center explains I-O Treatment vs. TKI Treatment | TKI is Still Standard of Care for Good-Risk Patients at Annual Meeting 2018
153 Views
2 years ago
Annual-Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
Suggested
Trending
00:00:50
Memorial Sloan Kettering Cancer Center Looked at Transcriptomic Signature | Outcomes For Patients Undergoing Antigenic Therapy
Free
157 Views
2 years ago
Annual-Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
00:00:32
Whether TKI & I-O Combinations are superior | Subgroups That Should Use One Over The Other
Free
209 Views
2 years ago
Annual-Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
00:00:33
Assign Genomic & Transcriptomic Features | To Treatment Subtypes to See Predictablity
Free
81 Views
2 years ago
Annual-Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
00:00:29
Understanding Tumor Microenvironment | Using Omics Platforms to Assign Treatment
Free
113 Views
2 years ago
Annual-Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
1
(current)
2
3
4
5
6
7
Liver Cancer
00:06:27
Eric J. Lehrer MD, MS @EricLehrer @IcahnMountSinai #ASTRO20 #livercancer The Development of Rib Fractures after Stereotactic Body Radiation Therapy to the Liver
Free
2 Views
2 months ago
ASTRO
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
0:07:43
Zarnie Lwin, MD @zarnielwin @RBWHFoundation LBA41 - LEAP-005: Phase II study of len plus pembro in pts with previously treated AST
Free
34 Views
3 months ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
0:15:00
John Bridgewater, MD, Ph.D. @uclcancer #livercancer Phase 2 Study FOENIX-CCA2 and Efficacy and Safety of Futibatinib
Free
69 Views
3 months ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
0:08:45
Marwan Fakih, MD @cityofhope #AACR20 Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
Free
18 Views
3 months ago
AACR
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
0:14:03
Christopher Jakubowski, MD @HopkinsMedicine #ASCO20 Response to Crizotinib in ROS1 Fusion–Positive Intrahepatic Cholangiocarcinoma
Free
11 Views
3 months ago
Annual-Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
0:09:49
Bruno Sangro, MD, Ph.D. @ClinicaNavarra @Adaptimmune #livercancer The unmet need in HCC patients, the ADP-A2AFP complete response and its potential
Free
108 Views
3 months ago
Cancer-News
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
0:04:01
Robin Kate Kelley, MD @UCSF Most effective way to combined a CTL4 inhibitor with a PDL1 inhibitor
Free
458 Views
4 months ago
Cancer-News
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
0:04:26
Robin Kate Kelley, MD @UCSF Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepato...
Free
5,683 Views
4 months ago
Cancer-News
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
0:04:23
Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311 - common questions asked - Timothy Heuer Ph.D. - twoXAR Pharmaceuticals @twoX...
Free
17 Views
4 months ago
Cancer-News
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
0:08:56
Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311 - Timothy Heuer Ph.D. - twoXAR Pharmaceuticals @twoXAR #AACR #livercancer
Free
21 Views
4 months ago
Cancer-News
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
00:08:59
Case Discussion: Immunotherapy for Advanced HCC
Free
12 Views
8 months ago
HMP CME
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
00:19:27
Novel Agents and Targets in Biliary Cancer
Free
12 Views
8 months ago
HMP CME
Add to
Want to watch this again later?
Sign in to add this video to a playlist.
Login
1
(current)
2
3